Lista, S;
Toschi, N;
Baldacci, F;
Zetterberg, H;
Blennow, K;
Kilimann, I;
Teipel, SJ;
... Hampel, H; + view all
(2017)
Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease.
Neurochemistry International
, 108
pp. 355-360.
10.1016/j.neuint.2017.05.010.
Preview |
Text
Zetterberg_Lista.pdf - Accepted Version Download (519kB) | Preview |
Abstract
We assessed the diagnostic accuracy of cerebrospinal fluid (CSF) neurofilament light chain (NFL) protein in the classification of patients with Alzheimer's disease (AD) and cognitively healthy control individuals (HCs) and patients with frontotemporal dementia (FTD) as comparisons. Particularly, we tested the performance of CSF NFL concentration in differentiating patient groups stratified by fluid biomarker profiles, independently of the severity of cognitive impairment (mild cognitive impairment (MCI) and AD dementia individuals), using a biomarker-guided descriptive classification system for AD. CSF NFL concentrations were examined in a multicenter cross-sectional study of 108 participants stratified in AD pathophysiology-negative (both CSF tau and the 42-amino acid-long amyloid-beta (Aβ) peptide (Aβ1-42)) (n = 15), tau pathology-positive only (n = 15), Aβ pathology-positive only (n = 13), AD pathophysiology-positive (n = 33), FTD (n = 9) patients, and HCs (n = 23), according to the biomarker-based classification system. The performance of CSF NFL in discriminating AD pathophysiology-positive patients from HCs is fair, whereas the ability in differentiating tau-positive patients from HCs is poor. The classificatory performance in distinguishing AD pathophysiology-positive patients from FTD is unsatisfactory.
| Type: | Article |
|---|---|
| Title: | Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.neuint.2017.05.010 |
| Publisher version: | http://doi.org/10.1016/j.neuint.2017.05.010 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | Neurofilament light chain protein; axonal degeneration; Alzheimer’s disease; Alzheimer’s disease pathophysiology; frontotemporal dementia; cognitive aging; mild cognitive impairment; biomarkers; biomarker-based diagnosis; cerebrospinal fluid. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10057933 |
Archive Staff Only
 |
View Item |
